CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 207 enrolled
Drug / intervention
vitamin E +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00363129
NCT00363129Phase 3Completed
CompareCT.gov

The Use of Vitamin E for Prevention of Chemotherapy Induced Peripheral Neuropathy: A Phase III Double-Blind Placebo Controlled Study

Alliance for Clinical Trials in Oncology·interventional·Posted Aug 15, 2006·Updated Jul 6, 2016

In Brief

A Phase 3 clinical trial evaluating vitamin E and placebo for Neurotoxicity and Unspecified Adult Solid Tumor, Protocol Specific. Completed, enrolled 207 participants across 69 sites.

Detailed Summary

RATIONALE: Vitamin E may prevent peripheral neuropathy caused by chemotherapy in patients with cancer. It is not yet known whether vitamin E is more effective than a placebo in preventing peripheral neuropathy caused by chemotherapy in patients receiving chemotherapy for cancer. PURPOSE: This randomized phase III trial is studying vitamin E to see how well it works compared with placebo in preventing peripheral neuropathy caused by chemotherapy in patients receiving chemotherapy for cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2006
Enrollment StartDec 1, 2006
Primary CompletionDec 1, 2010
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 19.9 years ago

Interventions

vitamin Edietary

Given orally

placeboother

Given orally